medigraphic.com
ISSN 1560-4381 (Print)

2016, Number 2

<< Back Next >>

Correo Científico Médico 2016; 20 (2)

Interferons modern therapeutic option in the treatment of basal cell carcinomas

Pérez LE, Batista OK, Pérez GO, Bello RI, Serrano MMV

Language: Spanish
References: 46
Page: 275-291
PDF size: 486.14 Kb.


ABSTRACT

Basocellular carcinoma is a skin malignant neoplasia that primarily affects white race people. Potential carcinogenic effect is etiologically related to the accumulative explosion of ultraviolet rays, with the deterioration of the ozone layer this phenomenon tends to increase in the last few years, thus the search of efficacious and safe alternative treatments constitutes a health system priority. Interferons are biotechnological products known to modify the biological response that, due to its antiproliferative and antiantigenic properties, are employed in modern therapy of basothelioma. A revision was carried out in the main databases, choosing 46 articles that update the molecular aspects and the clinical trials that justify the use of immune therapy, and essentially, the interferons, as a safe and efficacious strategy in the treatment of this type of neoplasia.


REFERENCES

  1. Karp G. Cell and Molecular Biology. Concepts and Experiments. 3 ed. New York: John Wiley and Sons; 2002.

  2. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C,The Le Q, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006 [citado 15 may 2014]; 440(7088): 1222-1226. Disponible en: http://www.nature.com/nature/journal/v440/n7088/full/nature04695.html

  3. Miguel Soca PE, Almaguer Herrera A, Ponce de León D, Sales Márquez H, Pérez Rodríguez H. El cáncer una enfermedad genética. CCM. 2007 [citado 15 may 2015]; 11(3). Disponible en: http://www.cocmed.sld.cu/no113/n113rev1.htm

  4. Emens LA. Survivin cancer. Cancer Biol Thera. 2004[citado 8 sep 2014]; 3(2): 180-183. Disponible en: http://www.landesbioscience.com/journals/cbt/emens3-2.pdf

  5. Coleman King S, Chen S. Analyzing the Cost of Preventing Nonmelanoma Skin Cancer. J Invest Derm.2009 [citado 30 oct 2015]; 129(12):2745-2746. Disponible en: http://www.jidonline.org/article/S0022-202X%2815%2934171-3/abstract

  6. Prado de Carvalho M, de Oliveira Filho RS, Carvalho Gomes H, Francescato Veiga D, Juliano Y, Masako Ferreira L. Autoestima en pacientes con carcinomas de piel. Rev Col Bras Cir.2007 [citado 15 may 2015]; 34(6):361-366. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912007000600002&lng=pt&nrm=iso&tlng=pt

  7. Lukaszuk L M, Cidral Muniz E, Leite Da Veiga M, Iribas J L. Aspectos epidemiológicos del cáncer no melanoma de piel en un servicio de dermatología de la ciudad de Santa Fe-Argentina 2007. Rev Argent Dermatol. 2008; 89(1):30-36.

  8. Bulliard JL, Panizzon RG, Levi F. Epidemiology of epithelial skin cancers. Rev Med Suisse. 2009[citado 2 nov 2015]; 5(200):884-888. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19438088

  9. World Health Organization. From Australia to Brazil: sun worshippers beware. Bull World Health Organ. 2009[citado 7 Jul 2014]; 87(8):574–575. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733274/

  10. Goset KP, Lorca BJ, Riveros TR. Radioterapia en Cáncer no Melanoma. Rev Chilena Dermatol. 2008; 24(3):218-221.

  11. Hansen C, Wilkinson D, Hansen M, Soyer HP. Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners. Arch Dermatol. 2009[citado 15 may 2015]; 145(11):1253-1260. Disponible en: http://archderm.jamanetwork.com/article.aspx?articleid=712273

  12. Bielsa I, Soria X, Esteve M, Ferrándiz. Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area. Br J Dermatol.2009 [citado 18 sep 2014]; 161(6):1341-1346. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2009.09468.x/abstract

  13. Bath-Hextall F,Leonardi-Bee J,Smith C,Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer. 2007[citado 25 ago 2014]; 121(9):2105–2108. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/ijc.22952/abstract

  14. Brash DE. Sunlight and the onset of skin cancer. Trends Genet. 1997[citado 15 de may 2014]; 13(10):410-414. Disponible en: http://www.sciencedirect.com/science/article/pii/S0168952597012468

  15. Madan V, Hoban P, Strange RC, Fryer AA, Lear JT. Genetics and risk factors for basal cell carcinoma. Br J Dermatol.2006 [citado 25 de jul 2014]; 154(Supl 1):5–7. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2006.07229.x/abstract

  16. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol. 2002; 146(1):20-23.

  17. Dlugosz A, Merlino G, Yuspa SH.Progress in cutaneous cancer research. J Investig Dermatol Symp Proc. 2002[citado 25 jun 2015]; 7(1): 17-26. Disponible en: http://www.sciencedirect.com/science/article/pii/S0022202X15529199

  18. Giannetti L, Consolo U, Magnoni C, Lo Muzio L. Apoptosis: Escaping strategies in human skin cancer (Review). Oncol Rep [citado 16 de mar 2015]; 11(2):401-405. Disponible en: https://www.spandidos-publications.com/or/11/2/401

  19. 19.Rodust PM,Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma: a role for antiapoptotic signalling pathways. Br J Dermatol. 2009 [citado 16 de mar 2015]; 161(Supl 3):107-115.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2009.09458.x/abstract

  20. Hernández Gil SJ, Buendía EA, Serrano OS. Patrones de exposición solar y tipos de cáncer de piel. Epidemiología y bioestadística. Piel.2006; 21(10):472-476.

  21. Buljan M, Bulat V, Situm M, Mihić LL, Stanić-Duktaj S. Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat. 2008[citado 16 mar 2015]; 47(1):25-30. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18714644

  22. Kirkham N. Tumors and Cysts of the epidermis. En: Elder DE, Elenitsas R, Johnson B, Jaworsky C. Lever´s histopathlogy of the skin. 9na ed. Philadelphia: Lippincott Wilkins; 2006.p.617-654.

  23. Seretis K, Thomaidis V, Karpouzis A, Tamiolakis D, Tsamis I. Epidemiology of surgical treatment of nonmelanoma skin cancer of the head and neck in Greece. Dermatol Surg. 2010; 36(1):15-22.

  24. Torezan L, Mautari Niwa AB, Festa Neto C. Terapia fotodinâmica em dermatologia: princípios básicos e aplicações. An Bras Dermatol. 2009[citado 20 ago 2014]; 84(5):445-459. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962009000500002&lng=en&nrm=iso

  25. Barrera MV, Herrera E. Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: situación actual y perspectivas. Actas Dermosifiliogr.2007 [citado 20 ago 2014]; 98(8):556-562. Disponible en: http://www.sciencedirect.com/science/article/pii/S0001731007701333

  26. Danopoulou I, Korfitis C, Koliarakis N, Trafalis DT. Rapid improvement of extensive non-melanoma skin cancers with combination of 13-cis-retinoic acid and radiotherapy: report of three cases. J BUON. 2009[citado 16 mar 2015]; 14(3):515-517. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19810148

  27. Brockmeyer NH, Poffhoff A, Bader A, Hochdorfer B, Schlottmann R, Rasokat H, et al. Treatment of skin cancer with interferon alfa-2b in HIV infected patients. Eur J Med Res.2006 [citado 28 oct 2015]; 11(1):27-32. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16504957

  28. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol.2009 [citado 30 oct 2015]; 145(12):1431-1438. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20026854

  29. Aguayo Leiva IR, Rıos-Bucetay L, Jaen-Olasolo P. Tratamiento quirúrgico vs no quirúrgico en el carcinoma basocelular. Actas Dermosifiliogr.2010 [citado 30 oct 2015]; 101(8):683–692. Disponible en: http://www.actasdermo.org/es/tratamiento-quirurgico-vs-no-quirurgico/articulo/S0001731010002796/

  30. Bin Yap FB. Clinical characteristics of basal cell carcinoma in a tertiary hospital in Sarawak, Malaysia. Int J Dermatol. 2010[citado 10 may 2014]; 49(2):176-179. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2009.04342.x/abstract

  31. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993[citado 16 may 2014]; 51(2):63-72. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.1993.tb01595.x/abstract

  32. García García I, González Delgado CA, Valenzuela Silva C, Hernández Bernal F, Ferrero-Bibilonia J, Soto Hernández R, et al. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004[citado 29 oct 2015]; 5(5):271-280. Disponible en: http://link.springer.com/article/10.2165/00126839-200405050-00003

  33. Labdo JE, Gibson KD, Sun S, Pestka S. Some species of human leukocyte interferon are glicosylated .Arch Biochem Biophys.1984 [citado 29 Oct 2015]; 232(1):422-426. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/6588921

  34. Darnell JE, kerr IM, Stark GR. Jak-stat pathways and transcriptional activation in response to interferons and other intracellular signaling proteins. Science. 1994 [citado 15 ago 2015]; 264(5164):1415-1421. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=JaK-Stat+Pathways+and+transcriptional+activation+in+response+to+interferons+and+other+extracellular+signaling+proteins

  35. Pestka S, Langer JA, Zoon KC, Samuel CE.Interferons and their actions. Annu Rev Biochem.1987 [citado 29 oct 2015]; 56:727-777. Disponible en: http://www.annualreviews.org/doi/abs/10.1146/annurev.bi.56.070187.003455

  36. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O.Induction of pulmonary indoleamine 2-3 dioxigenase by interferon. Proc Natl Acad Sci USA.1981 [citado 20 ago 2014]; 78(1):129-132.Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC319004/

  37. Sekar V, Atmar VJ, Joshi AR, Krim M, Kuchn GD. Inhibition of ornithine descarboxilase in human fibroblast cells by tipe I and tipe II interferons. Biochem Biophics Res Com.1983 [citado 25 ene 2014]; 114(3): 950-954. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/6412711

  38. Einat M, Resnitzky D, Kimchi A. Inhibitory effects of interferon on the expression of genes regulated by plateled derivated growth factor. Proc Natl Acad Sci USA. 1985 [citado 18 jun 2014]; 82(22):7608-7612. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Inhibitory+effects+of+interferon+on+the+expression+of+genes+regulated+by+plateled+derivated+growth+factor

  39. Bordens R, Grossberg S E, Trotta PP, Nagabhushan TL. Molecular and biologic characterization of recombinant interferon-alpha 2b. Semin. Oncol. 1997 [citado 28 Oct 2015];24(3):41–51. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/9208872

  40. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007[citado 18 dic 2014]; 24(1). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17253489

  41. 41.Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol.1990 [citado 28 ago 2014]; 23(4):694-700. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/2229497

  42. Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, Tanner DJ, et al. The effects of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Arch Dermatol.1990 [citado 16 ene 2014]; 126(8):1029-1032. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/2383027

  43. 43.Alpsoy E, Yikmaz E, Basaran E, Yazar S. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol. 1996 [citado 28 dic 2014]; 23(6):394-396. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/8708151

  44. Anasagasti Angulo L, García Vega Y, Barcelona Perez S, López Saura P, Bello Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer.2009 [citado 19 ago 2015]; 9:262. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724551/

  45. Buechner S, Wernli M, Bachmann F, Harr T, Erb P. Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer.2002 [citado 18 ene 2014]; 160:246-250.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12079220

  46. Fenton S, Kennedy S, Moriarty P. The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids. Acta Ophthalmol Scand. 2002[citado 28 oct 2015]; 80(6):674-675.Disponible en: http://onlinelibrary.wiley.com/doi/10.1034/j.1600-0420.2002.800623_3.x/full




2020     |     www.medigraphic.com